<html xmlns:v="urn:schemas-microsoft-com:vml"
      xmlns:o="urn:schemas-microsoft-com:office:office"
      xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 9">
<meta name=Originator content="Microsoft Word 9">
<link rel=File-List href="./Page2_files/filelist.xml">
<link rel=Edit-Time-Data href="./Page2_files/editdata.mso">
<link rel=OLE-Object-Data href="./Page2_files/oledata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title> </title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>jennifer</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>McDowall</o:LastAuthor>
  <o:Revision>14</o:Revision>
  <o:TotalTime>1208</o:TotalTime>
  <o:Created>2004-12-20T12:15:00Z</o:Created>
  <o:LastSaved>2005-01-07T11:26:00Z</o:LastSaved>
  <o:Pages>1</o:Pages>
  <o:Words>526</o:Words>
  <o:Characters>2999</o:Characters>
  <o:Company>EMBL-EBI</o:Company>
  <o:Lines>24</o:Lines>
  <o:Paragraphs>5</o:Paragraphs>
  <o:CharactersWithSpaces>3682</o:CharactersWithSpaces>
  <o:Version>9.6926</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:Zoom>75</w:Zoom>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:16.0pt;
	font-family:Arial;
	mso-font-kerning:16.0pt;}
h2
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:14.0pt;
	font-family:Arial;
	font-style:italic;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:72.0pt 90.0pt 72.0pt 90.0pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
-->
</style>
<!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1029"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-GB link=blue vlink=purple style='tab-interval:36.0pt'>

<div class=Section1>

<p class=MsoNormal><a href="http://www.ebi.ac.uk/interpro/"
title="To the InterPro database"><span style='color:windowtext;text-decoration:
none;text-underline:none'><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:141pt;
 height:45pt' o:ole="">
 <v:imagedata src="./Page2_files/image001.wmz" o:title=""/>
</v:shape><![endif]--><![if !vml]><img border=0 width=188 height=60
src="./Page2_files/image002.gif" v:shapes="_x0000_i1025"><![endif]><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="Word.Picture.8" ShapeID="_x0000_i1025"
  DrawAspect="Content" ObjectID="_1166602330">
 </o:OLEObject>
</xml><![endif]--></span></a></p>

<h1 align=center style='text-align:center'><span style='font-size:28.0pt;
mso-bidi-font-size:16.0pt;color:navy'>Phenylalanine hydroxylase<o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h2><span style='color:navy;font-style:normal'>Phenylketonuria, Loss of Control<o:p></o:p></span></h2>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoBodyText><span style='mso-tab-count:1'>            </span>Any loss
of PheH activity can result in the accumulation of Phe and its neurotoxic metabolites,
as well as in the depletion of tyrosine and methionine, the latter being needed
for the formation of catecholamine neurotransmitters such as dopamine, as well
as for protein synthesis.<span style="mso-spacerun: yes">  </span>The outcome
of such metabolic changes can often be neurological disease.<span
style="mso-spacerun: yes">  </span></p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>Several
hundred different mutations in the PheH gene have been characterised over the
entire length of the protein.<span style="mso-spacerun: yes">  </span>Many of
these have been recorded and annotated in the PheH (or PAH) database, <a
href="http://www.pahdb.mcgill.ca/" title="Phenylalanine Hydroxylase Database">http://www.pahdb.mcgill.ca/</a>,
which provides expression analysis data.<span style="mso-spacerun: yes"> 
</span>These mutations result in a wide spectrum of phenotypes that range in
severity from mild hyperphenylalaninaemia (HPA) (serum Phe levels of 400-600 <span
style='font-family:Symbol'>m</span>mol/L) with a low risk of impaired cognitive
development, to phenylketonuria (PKU) (<span style='color:blue'><a
href="http://www.ncbi.nih.gov/entrez/dispomim.cgi?id=261600"
title="Online Mendelian Inheritance in Man - Phenylalanine Hydroxylase"><span
style='text-decoration:none;text-underline:none'>MIM:261600</span></a></span>)
characterised by high serum Phe levels (&gt;1200 <span style='font-family:Symbol'>m</span>mol/L),
which if left untreated causes severe progressive mental retardation, epilepsy and
microcephaly; these symptoms can largely be prevented by a Phe-restricted
diet.<span style="mso-spacerun: yes">  </span>In addition to mutations in PheH
gene, about 2% of cases arise from mutations in the enzymes that synthesise the
BH<sub>4</sub> cofactor.<span style="mso-spacerun: yes">  </span>HPA and PKU
are autosomal recessive disorders, with an average incidence of 1/10,000 in
Caucasian populations.</p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>Most of the
mutations in PheH are point (missense) mutations that most frequently result in
protein misfolding.<span style="mso-spacerun: yes">  </span>Misfolded monomers
tend to associate through exposed hydrophobic surfaces to form aberrant
oligomers that can irreversibly form large protein aggregates.<span
style="mso-spacerun: yes">  </span>Cells have a quality control system to
remove mutant polypeptides so as to prevent the potentially damaging effects of
protein aggregates, usually through <a
href="http://www.ebi.ac.uk/interpro/potm/2004_12/Page1.htm"
title="Protein of the Month:  UBIQUITIN">ubiquitinylation</a>.<span
style="mso-spacerun: yes">  </span>All forms of the mutant enzyme, including
the misfolded polypeptide, aberrant oligomers and large protein aggregates, are
subjected to an increased rate of proteolytic degradation, which reduces the
intracellular levels of mutant PheH and consequently decreases Phe catabolism
leading to HPA or PKU diseases.</p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>A small number
of missense mutations result in decreased enzyme affinity for either substrate
or BH<sub>4</sub> cofactor binding, or affect allosteric regulatory properties
of the enzyme.<span style="mso-spacerun: yes">  </span>For example, some PheH
deficiencies are responsive to the oral administration of BH<sub>4</sub>
cofactor.<span style="mso-spacerun: yes">  </span>BH<sub>4</sub>&#8209;responsive
PheH deficiencies all show residual catalytic activity, but have a reduced
affinity for BH<sub>4</sub> cofactor binding resulting from mutations in the
catalytic domain.<span style="mso-spacerun: yes">  </span>The administration of
BH<sub>4</sub> is thought to increase the binding of the cofactor, as well as
to protect the mutant enzyme from misfolding and degradation by increasing
protein stability, thereby acting as a chemical chaperone.</p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>Other genes
may be involved in the severity of the PKU phenotype.<span style="mso-spacerun:
yes">  </span>For instance, the enzyme monoamine oxidase type B (MOAB) can
degrade phenylethylamine, a toxic Phe metabolite that can cause brain
injury.<span style="mso-spacerun: yes">  </span>It is thought that MOAB might
be a modifier gene in PKU, because different levels of phenylethylamine have
been found in PKU patients with similar levels of Phe.</p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1 align=center style='text-align:center'>Next:<span style="mso-spacerun:
yes">  </span><a href="Page3.htm">What InterPro Tells Us</a></h1>

<h1 align=center style='text-align:center'>Previous:<span style="mso-spacerun:
yes">  </span><a href="Page1.htm">Phenylalanine hydroxylase, an essential role</a></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

</div>

</body>

</html>
